Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Tag Archive for: Oxford Biomedica
British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bio’s lead product, DSG3-CAART.
Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.